Motor cortex beta oscillations reflect motor skill learning ability after stroke

Svenja Espenhahn, Holly E Rossiter, Bernadette CM van Wijk, Nell Redman, Jane M Rondina,

Joern Diedrichsen, Nick S Ward

Supplementary Material

Methods

Clinical assessment

Stroke-related impairment was evaluated using the following standardized measures: the Action Research Arm Test (ARAT; 0–57) (Yozbatiran *et al.*, 2008), the Nine-Hole-Peg Test (NHPT; time to place 9 pegs into 9 holes) (Mathiowetz *et al.*, 1985*b*) and grip strength using a dynamometer (Mathiowetz *et al.*, 1985*a*). All scores were normalized to values of the unaffected arm of each patient. Since sensory loss is common after stroke (Tyson *et al.*, 2008), patients' tactile sensitivity was tested using the Fugl-Meyer (FM) (Fugl-Meyer *et al.*, 1975) sensation and passive joint motion scale (0–12). In order to create a compound impairment score unaffected by floor and ceiling effects in individual scores (Ward *et al.*, 2003; Rossiter *et al.*, 2014), a principle component analysis (PCA) was performed on all measures (a lower PCA score corresponds to greater impairment).

Cognitive functioning was assessed using the Sustained Attention to Response Test (SART; max error score 225). To control for the effect of fatigue and sleep, patients completed computerised versions of the Fatigue Severity Scale 7 (FSS-7; 0–7) (Krupp *et al.*, 1989; Johansson *et al.*, 2014), the Neurological Fatigue Index (NFI; 0–7) (Mills *et al.*, 2012)) and the St. Mary's Hospital sleep questionnaire (adapted from (Ellis *et al.*, 1981)) for the nights preceding testing. In order to generate a fatigue severity score, a PCA was performed on FSS and NFI ratings (lower PCA scores reflect lower levels of fatigue).

Age	Sex	Months	Lesion	Affected	Suspected	ARAT	NHPT	Grip	Tactile	FSS-7	NFI
		since	side	hand	stroke etiology			strength	sensitivity		
		stroke									
74	F	136	R	ND (L)	LACI	100	91	97	12	3.7	2.2
71	Μ	41	R	ND (L)	LACI	100	77	92	12	2.8	1.5
57	Μ	80	R	ND (L)	anterior	100	97	93	12	1.6	1.8
					thalamus						
50	М	43	L	D (R)	posterior MCA	98	68	89	12	6.1	2.5
63	Μ	122	L	D (R)	striatocapsular	100	91	90	12	3.6	1.8
63	Μ	70	L	D (R)	LACI	100	102	116	11	5.0	3.0
63	F	44	R	ND (L)	frontal lobe	100	95	67	12	-3.1	2.9
71	Μ	220	R	ND (L)	LACI	96	50	67	11	4.0	2.5
56	Μ	49	R	ND (L)	thalamus	100	95	76	10	2.9	2.2
63	F	71	L	AD (L)	LACI	100	96	55	12	2.7	2.5
60	Μ	42	L	D (R)	anterior MCA	100	86	104	11	2.6	2.8
73	Μ	128	L	D (R)	LACI	100	89	87	12	3.9	2.4
71	F	57	R	ND (L)	LACI	100	124	39	12	4.4	2.6
75	F	136	L	D (R)	PCA	100	94	54	12	3.9	2.0
56	М	83	R	ND L)	hypothalamus	100	89	57	12	3.7	3.0
58	F	105	L	D (R)	anterior MCA	100	107	24	10	4.4	3.0

1 Supplementary Table 1: Stroke patient characteristics.

2 *M: Male; F: Female; R: Right; L: Left; ND: Non-dominant; D: Dominant; AD: Ambidextrous; LACI: Lacunar infarct; MCA: Middle*

3 cerebral artery; PCA: Posterior cerebral artery; ARAT: Action Research Arm Test; NHPT: Nine Hole Peg Test in peg/s; FSS-7: Fatigue

4 Severity Scale; NFI: Neurological Fatigue Index

5

6

7 Individual target velocity

Prior to the training, the average velocity with which the target moved along the arc was 8 individually determined in order to ensure that the task was of equal difficulty for everyone at the 9 beginning of the training and left enough room for improvement in performance. For this purpose, 10 we implemented an adaptive staircase procedure, which, on any given trial, adjusted 11 12 (increased/decreased) the target velocity dependent on the subject's preceding performance until a pre-specified criterion range was reached. On average, patients reached the criterion in 15.5 ± 5.1 13 trials and the number of trials required was comparable to the control subjects ($t_{(1,34)}=0.96$, 14 15 p=0.082). The individually determined target velocity with which subjects were subsequently trained on the continuous tracking task was applied to all sessions. Of note, the target velocity with 16 which patients were trained (mean velocity \pm SD = 45.38 \pm 5.22 deg/s) was significantly slower 17 compared to the control group (mean velocity \pm SD = 51.28 \pm 9.43 deg/s) [*t*(34)=-2.24, *p*=0.032]. 18

19



20

Mean RMSE per block — fitted RMSE values

Supplementary Figure 1: Linear regression approach for exemplary patient. Dots represent individual blocks of an example patient during training and retest sessions of repeated sequence only. Black lines represent linear regression models across 5 blocks at the beginning and end of individual sessions. Corrected performance estimates were derived from these linear regression models at six different time points (T0 = first block of training, T1 = last block of training, T2 = first block of retest1, T3 = last block of retest1, T4 = first block of retest2, and T5 = last block of retest2) and used to subsequently assess changes in performance with training.

28

29

- 30 Supplementary Table 2: Potential predictors of performance at T2 and T4 included in the
- 31 regression approach with LOOCV.

	Performance at T2	Performance at T4
Pre-training beta power measures		
Pre-BBc	•	♦
Pre-BBi	♦	•
Pre-MRBDc	♦	•

Pre-MRBDi	•	•
Pre-PMBRc	•	•
Pre-PMBRi	•	•
Post-training beta power measures		•
Post1-BBc	•	•
Post1-BBi	•	•
Post1-MRBDc	•	•
Post1-MRBDi	•	•
Post1-PMBRc	•	•
Post1-PMBRi	•	•
Post2-BBc		•
Post2-BBi		•
Post2-MRBDc		•
Post2-MRBDi		•
Post2-PMBRc		•
Post2-PMBRi		•
Motor performance at		
T0	•	•
T1	•	•
T2		•
T3		•
Demographic information		
Age	•	•
Motor function	•	•
Cognitive function	•	•
Sleep characteristics	•	•

	Group	Time	Sequence Type	Interactions
Performa	nce changes ac	cross initial training		
T0 vs T1				time x group:
	$F_{(1,33)}=0.01$,	<i>F</i> (1,34)= 9.69 ,	<i>F</i> (1,34)=15.73,	F (1,34)= 6.70 ,
	<i>p</i> =0.330	$p=0.004, \eta_{p2}=0.222$	<i>p</i> <0.001, η _{p2} =0.316	<i>P=0.014</i> ,
				$\eta_{P^2}=0.165$
				time x sequence:
				<i>F</i> (1,34)=16.74,
				<i>p<0.001</i> ,
				$\eta_{p2}=0.330$
Performa	nce changes af	ter time delay (retest)	l, retest2)	
T1 vs T2				sequence x groups
	<i>F</i> (1,34)= 5.84 ,	$F_{(1,34)}=20.96,$	<i>F</i> (1,34)= 48.79 ,	F (1,34) =4.39 ,
	<i>p=0.021</i> ,	<i>p</i> <0.001, η _p ₂ =0.381	<i>p</i> <0.001, η _{<i>p</i>2} =0.589	<i>P=0.044</i> ,
	η _{p2} =0.147			η _p 2=0.114
T3 vs T4				sequence x group:
	<i>F</i> (1,34)= 6.84 ,	<i>F</i> (1,34)= 8.41 ,	F (1,34)= 44.83 ,	F (1,34)= 5.56 ,
	p=0.013,	<i>p</i> =0.006, η _{p2} =0.198	<i>p</i> <0.001, η _{p2} =0.569	<i>p=0.024</i> ,
	η _{p2} =0.167			$\eta_{p2}=0.140$
				time x sequence:
				F (1,34)= 9.07 ,
				<i>p=0.005</i> ,
				$\eta_{P^2}=0.211$
Overall p	erformance ch	anges		
T0 vs T2				time x group:
				<i>F</i> (1,34)= 9.61 ,

Supplementary Table 3: ANOVA results of patients' motor performance at different time points
during the motor learning process relative to controls.

	$F_{(1,34)}=1.03$,	F (1,34)= 50.39 ,	<i>F</i> (1,34)=20.49,	<i>p=0.004</i> ,
	<i>p</i> =0.317	<i>p</i> <0.001, η _{<i>p</i>2} =0.597	<i>p</i> <0.001, η _{<i>p</i>2} =0.376	$\eta_{p2}=0.220$
				time x sequence: F _(1,34) =29.53, P<0.001, η _P 2=0.465
T0 vs T4				time x group:
	$F_{(1,34)}=1.30$,	F (1,34)= 56.25 ,	<i>F</i> (1,34)= 6.99 ,	<i>F</i> (1,34)=10.33,
	<i>p</i> =0.262	<i>p</i> <0.001, η _{<i>p</i>2} =0.623	$p=0.012, \eta_{P^2}=0.171$	<i>p=0.003</i> ,
				$\eta_{P^2}=0.233$
				time x sequence:
				<i>F</i> (1,34)=12.74,
				<i>P=0.001</i> ,
				$\eta_{p2}=0.273$

Significant effects are indicated in bold. T0: beginning of training session; T1: end of training session; T2: beginning of retest1; T3: end of retest1; T4: beginning of retest2.

- 35
- 36

37 Supplementary Table 4: ANOVA results for spectral power measures

	Group	Hemisphere		Session	Interactions
BB					
	$F_{(1,34)}=0.21,$ p=0.653	$F_{(1,34)}=1.80,$ p=0.188		$F_{(2,68)}$ =5.90, p=0.004, n_{p2} =0.148	n.s.
MRBD					
	$F_{(1,34)}=2.22,$ p=0.146	$F_{(1,34)}=21.06,$ $\eta_{p2}=0.383$	p<0.001,	$F_{(2,68)}=5.94,$ $p=0.004, \eta_{p2}=0.149$	n.s.

PMBR

$F_{(1,34)}=0.31,$	$F_{(1,34)}=7.25,$	p=0.011,	$F_{(2,68)}=3.29,$	n.s.
<i>p</i> =0.576	η _{p2} =0.176		$p=0.043, \eta_{p2}=0.088$	

Significant effects are indicated in bold. BB: Pre-movement baseline beta; MRBD: Movement-Related Beta Desynchronization; PMBR: Post-Movement Beta Rebound; n.s.: not significant.